NYSE:JNJ

Johnson & Johnson (JNJ) Stock Forecast, Price & News

$155.06

+0.69 (+0.45%)

(As of 05/31/2023 ET)

Compare

Today's Range: $153.85
▼
$155.69
50-Day Range: $151.13
▼
$166.11
52-Week Range: $150.11
▼
$183.35

Volume: 10.60 million shs
Average Volume: 5.42 million shs
Market Capitalization: $402.96 billion

P/E Ratio: 32.44
Dividend Yield: 3.07%
Price Target: $173.00

Johnson & Johnson MarketRank™ Forecast

Analyst Rating: Hold
2.46 Rating Score
Upside/Downside: 11.6% Upside
$173.00 Price Target
Short Interest: Healthy
0.52% of Float Sold Short
Dividend Strength: Strong
Based on Four Factors
Sustainability: -1.98
Upright™ Environmental Score
News Sentiment: 0.22
Based on 20 Articles This Week
Insider Trading: Selling Shares
$164,249 Sold Last Quarter
Proj. Earnings Growth: 3.28%
From $10.66 to $11.01 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.74 out of 5 stars

Medical Sector

70th out of 1,006 stocks

Pharmaceutical Preparations Industry

25th out of 492 stocks

3.2

Analyst's Opinion

Consensus Rating
Johnson & Johnson has received a consensus rating of Hold. The company's average rating score is 2.46, and is based on 6 buy ratings, 7 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $173.00, Johnson & Johnson has a forecasted upside of 11.6% from its current price of $155.06.
Amount of Analyst Coverage
Johnson & Johnson has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
0.52% of the float of Johnson & Johnson has been sold short.
Short Interest Ratio / Days to Cover
Johnson & Johnson has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Johnson & Johnson has recently increased by 5.81%, indicating that investor sentiment is decreasing significantly.

3.3

Dividend Strength

Dividend Yield
Johnson & Johnson pays a meaningful dividend of 3.08%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Johnson & Johnson has been increasing its dividend for 62 years.
Dividend Coverage
The dividend payout ratio of Johnson & Johnson is 99.58%. Payout ratios above 75% are not desirable because they may not be sustainable.
Dividend Sustainability
Based on earnings estimates, Johnson & Johnson will have a dividend payout ratio of 43.23% next year. This indicates that Johnson & Johnson will be able to sustain or increase its dividend.

3.9

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Johnson & Johnson has received a 52.68% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Ustekinumab", "Clinical research services for physical health", "Rivaroxaban", "Daratumumab", "Ibrutinib", and "HIV medication" products. See details.
Environmental Sustainability
The Environmental Impact score for Johnson & Johnson is -1.98.

1.2

News and Social Media Coverage

News Sentiment
Johnson & Johnson has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 20 news articles for Johnson & Johnson this week, compared to 22 articles on an average week.
Search Interest
Only 214 people have searched for JNJ on MarketBeat in the last 30 days. This is a decrease of -42% compared to the previous 30 days.
MarketBeat Follows
Only 60 people have added Johnson & Johnson to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Johnson & Johnson insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $164,249.00 in company stock.
Percentage Held by Insiders
Only 0.20% of the stock of Johnson & Johnson is held by insiders.
Percentage Held by Institutions
67.94% of the stock of Johnson & Johnson is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Johnson & Johnson are expected to grow by 3.28% in the coming year, from $10.66 to $11.01 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Johnson & Johnson is 32.44, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 137.60.
Price to Earnings Ratio vs. Sector
The P/E ratio of Johnson & Johnson is 32.44, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 130.58.
Price to Earnings Growth Ratio
Johnson & Johnson has a PEG Ratio of 2.63. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Johnson & Johnson has a P/B Ratio of 5.69. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Johnson & Johnson (NYSE:JNJ) Stock

Johnson & Johnson is a US-based multinational pharmaceutical company that started in the early 1870s. Robert Wood Johnson began training as a pharmacist at 16 and founded his 1st company in 1873. That company would be disbanded by 1886 when Johnson joined his brothers to form today's entity. The company’s first line of products was sterile surgical dressings which were soon followed up by household products and medical guides.

Today, Johnson & Johnson is one of the world’s largest companies. It is ranked 36th on the 2021 Fortune 500 list and is a Dow Jones Industrial Average member. The company operates via 250 subsidiaries with operations in 60 countries and product sales in 175. As of 2021, annual sales were in the range of $95 billion and growing. The company is also a leader in equality and the advancement of women’s rights. Johnson & Johnson’s workforce was nearly 50% female by 1910, and many held significant positions of responsibility.

Among the company’s many advances in health care is the advancement of sterile conditions to prevent postoperative and secondary infections. Products include sterile gauze, cotton and dressings, and the development of the industrial sterilization process. However, the product that launched the company to success was the combination of a sterile dressing with tape. The company called the new products Band-Aids, which is now synonymous with small, prepackaged bandages. Another major win for the company was Johnson & Johnson Baby Soap.

Today, Johnson & Johnson operates in 3 segments: Pharmaceutical, Consumer Health and MedTech. The Consumer Health segment alone covers brands like Aveeno, Listerine, Tylenol, Zyrtec, Band-Aid and Neosporin, which are among the world’s most recognizable brands. The company’s purpose is to “blend science and ingenuity to change the trajectory of health for humanity profoundly”.

The Pharmaceutical segment offers products in all segments of the healthcare spectrum and has partnerships to develop new drugs with at least 10 other major healthcare providers and dozens of smaller research facilities. Products are offered wholesale to retailers and through healthcare systems. The MedTech segment develops and manufactures various healthcare devices and diagnostic tools. Among the many recognizable products from this segment are ACUVUE contact lenses.

Johnson & Johnson went public in 1944 and began paying dividends soon after. The company began increasing its dividend payment in 1962 and has increased it yearly. The company is a member of the Dividend Aristocrat Index and qualifies as a Dividend King with more than 50 years of consecutive annual increases. The company employs more than 142,000 individuals and serves more than 1 billion daily. Regarding the company’s health, its track record of dividend payments is backed up by a AAA credit rating. Johnson & Johnson is one of only 2 US corporations with such a rating and is more trusted than the US government.

The company announced plans to split into two publicly traded companies in 2021. The move is expected to be complete in late 2023 and will result in a Consumer Health company and a Pharmaceutical company.

Receive JNJ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Johnson & Johnson and its competitors with MarketBeat's FREE daily newsletter.

JNJ Stock News Headlines

May 31, 2023 | marketbeat.com

The How and Why of Investing in Biotech Stocks (JNJ)

One fascinating sector to invest in is the biotech sector which includes companies involved in the research and development of therapeutics and vaccines

May 23, 2023 | marketbeat.com

Will Dividends Take Center Stage In The Second Half Of 2023? (JNJ)

The NYSE Composite's sideways trade since early 2021 could be a warning sign, suggesting that a shift toward dividend strategies may be prudent.

June 1, 2023 | Edge On The Street (Ad)

Graphite versus Lithium - What Investors Should Know

Over 18 million EVs will be cruising U.S roads by 2030. And every one million EVs manufactured will require 82,000 tons of the metal graphite for their batteries. That's a total of 1,476,000 tons of graphite! Graphite is actually the largest component of EV batteries - NOT lithium. Experts warn of a massive graphite shortfall, especially since North America currently has no operating graphite mines.

May 15, 2023 | marketbeat.com

Is Novavax Finally Turning Things Around? (JNJ)

Vaccine developer Novavax Inc. (NASDAQ: NVAX) stock shot up 28% following its Q1 2023 earnings report. The company specializes in vaccines for infectious disea

May 15, 2023 | marketbeat.com

UnitedHealth Group is an AI Stock That Isn't Beating Expectations (JNJ)

Although it's a pioneer in AI, UnitedHealth Group is not enjoying the halo effect on AI stocks, but with more clarity on future growth that should change

May 12, 2023 | marketbeat.com

3 Recession-Proof Stocks With Nice Dividends (JNJ)

Certain sectors like consumer staples and health care tend to outperform during economic turbulence. These three stocks are good names to own for the bad times.

May 10, 2023 | marketbeat.com

5 Best Healthcare Sector ETFs (JNJ)

What do you need to know about investing in healthcare ETFs? Learn more about both healthcare and ETFs with MarketBeat.

May 9, 2023 | marketbeat.com

J&J Kenvue Spinoff Aims To Give Investors A Healthy Return (JNJ)

Johnson & Johnson spinoff Kenvue had the biggest IPO since 2021, raising $3.8 billion. Kenvue's brands include Band-Aid, Tylenol, Neutrogena and Listerine.

June 1, 2023 | Edge On The Street (Ad)

Graphite Shortage Could Derail the $7 Trillion EV Transition

Graphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.

May 8, 2023 | marketbeat.com

May 5, 2023 | marketbeat.com

Regeneron Beats Q1 Views, But Stock Drops On Weak Eye Med Sales (JNJ)

Regeneron reported better-than-expected Q1 earnings and revenue, but its Eylea sales fell, losing ground to Roche's newly launched Vabysmo.